pharmaceuticals

upgrade

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

GW Pharmaceuticals PLC (NASDAQ: GWPH) was recently listed as the top medical marijuana stock for National Weed Day, but other things are going on here besides weird holidays. GW recently ...
Read Full Story »
145922793

Can La Jolla Pharma Shares Really Double?

Health care is still going strong in April, and biotech and emerging pharmaceutical stocks still have huge gains so far in 2015. La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen ...
Read Full Story »
knees

Is Ampio at Risk of Imploding?

Companies in the biotech and pharmaceuticals field are generally riskier than other companies because a single failed study could make or break the company, similar to what happened with Ampio ...
Read Full Story »
marijuana leaf

Is GW Pharmaceuticals the Perfect Cannabis Stock on National Weed Day?

With Monday, April 20, being National Weed Day (a 4:20 takeoff), 24/7 Wall St. wondered which marijuana stocks were either the best in class or had the most upside. The ...
Read Full Story »
Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »
Biotechnology word cloud

4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

Biotech has been one hot sector again in 2015. Two key biotech exchange traded funds are up 20% or so on average year-to-date. 247 Wall St. could not help but ...
Read Full Story »
biotech

5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015

The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight. The ...
Read Full Story »
biotech

Akebia Hits New Low After Pricing Secondary Offering

Akebia Therapeutics Inc. (NASDAQ: AKBA) announced the pricing for its secondary offering Thursday evening. A total of 7.27 million shares of common stock were registered for the offering at a ...
Read Full Story »
Prescription drugs

Why Mylan Still Has Upside After Perrigo

The health care sector has been on fire this year and companies in the pharma, biotech and generic spaces are using mergers and acquisitions to fuel their next round of ...
Read Full Story »
generic drugs

Can Perrigo Get More From Mylan?

Just before lunchtime on Wednesday, generic drug maker Mylan N.V. (NASDAQ: MYL) proposed to acquire rival Perrigo Co. PLC (NYSE: PRGO) for $205 per share in cash and stock. Perrigo, ...
Read Full Story »
Prescription drugs

4 Big Pharmaceutical Stocks to Buy for the Rest of 2015

While most people consider big pharmaceutical stocks very defensive, the fact of the matter is that they offer investors terrific growth and income possibilities, which can lead to outstanding total ...
Read Full Story »
152498601

Is Nymox a Fluke or Is It Back?

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) has been around for a long time, but within the past five years the stock has literally fallen off a cliff. Suddenly, its shares rallied ...
Read Full Story »
generic drugs

Does the Mylan Secondary Make Its Stock Cheap?

Mylan N.V. (NASDAQ: MYL) announced that it would have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the offering would be valued at $2.08 billion. Total assets owned by ...
Read Full Story »
generic drugs

Are Auspex Shareholders Getting Enough in the Buyout?

It is always a fair question to ask if shareholders are getting enough whenever a buyout is on the table. News broke Monday that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will ...
Read Full Story »
investor research

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

There are two events in the biotech world that can quickly bring down the price of a stock. One is to have a failed or, sometimes worse, a misunderstood clinical ...
Read Full Story »